Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Position Trimmed by Nuveen Asset Management LLC

Nuveen Asset Management LLC trimmed its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 32.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 87,506 shares of the company’s stock after selling 42,360 shares during the quarter. Nuveen Asset Management LLC owned about 0.23% of Entrada Therapeutics worth $1,513,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. SG Americas Securities LLC grew its stake in shares of Entrada Therapeutics by 44.0% in the 4th quarter. SG Americas Securities LLC now owns 14,036 shares of the company’s stock worth $243,000 after purchasing an additional 4,291 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Entrada Therapeutics in the fourth quarter worth $137,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Entrada Therapeutics by 6.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company’s stock worth $3,408,000 after buying an additional 11,143 shares during the last quarter. AlphaQuest LLC acquired a new position in Entrada Therapeutics during the 4th quarter valued at $70,000. Finally, American Century Companies Inc. raised its stake in Entrada Therapeutics by 17.7% during the 4th quarter. American Century Companies Inc. now owns 59,710 shares of the company’s stock valued at $1,032,000 after purchasing an additional 8,985 shares during the last quarter. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Trading Up 1.2%

Shares of NASDAQ TRDA opened at $8.24 on Wednesday. The firm has a market capitalization of $312.73 million, a PE ratio of 5.18 and a beta of 0.04. Entrada Therapeutics, Inc. has a 1 year low of $7.10 and a 1 year high of $21.79. The firm’s 50-day moving average is $8.29 and its 200-day moving average is $12.51.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.36. The firm had revenue of $8.75 million for the quarter, compared to the consensus estimate of $10.98 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. As a group, equities research analysts anticipate that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a report on Tuesday, May 20th.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.